Consistently, our study revealed that patients with PTPRD/PTPRT mutations who did not receive ICI treatment in TCGA pan-cancer cohort had a worse clinical outcome, compared with their WT counterparts, indicating that patients with PTPRD/PTPRT mutations may have a worse impact on patients across multiple cancer types. This evidence concerns the gene PTPRD and cancer.